Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK.

Oncogene. 2019 Jul 9. doi: 10.1038/s41388-019-0862-y. [Epub ahead of print]

PMID:
31289363
2.

FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS.

Carcinogenesis. 2019 May 7. pii: bgz062. doi: 10.1093/carcin/bgz062. [Epub ahead of print] No abstract available.

PMID:
31063534
3.

Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease.

Amano H, Chaudhury A, Rodriguez-Aguayo C, Lu L, Akhanov V, Catic A, Popov YV, Verdin E, Johnson H, Stossi F, Sinclair DA, Nakamaru-Ogiso E, Lopez-Berestein G, Chang JT, Neilson JR, Meeker A, Finegold M, Baur JA, Sahin E.

Cell Metab. 2019 Jun 4;29(6):1274-1290.e9. doi: 10.1016/j.cmet.2019.03.001. Epub 2019 Mar 28.

PMID:
30930169
4.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
5.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

6.

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.

Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B.

Mol Ther Nucleic Acids. 2019 Mar 1;14:301-317. doi: 10.1016/j.omtn.2018.11.019. Epub 2018 Dec 13.

7.

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25.

8.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
9.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.

PMID:
30305341
10.

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr.

Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3.

11.

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK.

Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y.

12.

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S.

Clin Cancer Res. 2018 Nov 15;24(22):5697-5709. doi: 10.1158/1078-0432.CCR-17-3125. Epub 2018 Jul 16.

PMID:
30012564
13.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122387. doi: 10.1172/jci.insight.122387. eCollection 2018 Jun 7. No abstract available.

14.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. eCollection 2018 Jun 7. No abstract available.

15.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

16.

Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.

Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B.

Clin Cancer Res. 2018 Sep 1;24(17):4225-4241. doi: 10.1158/1078-0432.CCR-17-1959. Epub 2018 May 10.

PMID:
29748184
17.

ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L.

Cell Rep. 2018 Apr 17;23(3):823-837. doi: 10.1016/j.celrep.2018.03.078.

18.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK.

Cancer Res. 2018 Jun 15;78(12):3233-3242. doi: 10.1158/0008-5472.CAN-16-1701. Epub 2018 Apr 16.

19.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

20.

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.

Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr, Sood AK, von Delft F, Ahmed AA.

Nat Commun. 2018 Feb 2;9(1):476. doi: 10.1038/s41467-017-02811-7.

21.

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli M.

Nat Commun. 2018 Jan 31;9(1):461. doi: 10.1038/s41467-018-02851-7.

22.

HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.

Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC.

Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.

23.

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.

Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G.

Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262. doi: 10.1016/j.omtn.2017.06.023. Epub 2017 Jul 5.

24.

RNA interference-based therapy and its delivery systems.

Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK.

Cancer Metastasis Rev. 2018 Mar;37(1):107-124. doi: 10.1007/s10555-017-9717-6. Review.

25.

MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.

Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV.

Cancer Res. 2018 Jan 1;78(1):64-74. doi: 10.1158/0008-5472.CAN-17-0815. Epub 2017 Nov 27.

26.

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).

Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK.

Oncogene. 2018 Feb 8;37(6):722-731. doi: 10.1038/onc.2017.348. Epub 2017 Oct 23.

27.

Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.

Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G.

Cell Discov. 2017 Sep 12;3:17029. doi: 10.1038/celldisc.2017.29. eCollection 2017.

28.

Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK.

Nat Commun. 2017 Aug 21;8(1):310. doi: 10.1038/s41467-017-00411-z.

29.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. eCollection 2017 Aug 17.

30.

Chitosan Nanoparticles for miRNA Delivery.

Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK.

Methods Mol Biol. 2017;1632:219-230. doi: 10.1007/978-1-4939-7138-1_14.

PMID:
28730442
31.

miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.

Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P.

Sci Rep. 2017 Jun 15;7(1):3614. doi: 10.1038/s41598-017-03972-7.

32.

Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.

Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V.

Clin Cancer Res. 2017 Sep 15;23(18):5611-5621. doi: 10.1158/1078-0432.CCR-16-3272. Epub 2017 Jun 13.

33.

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.

Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA.

Genome Biol. 2017 May 24;18(1):98. doi: 10.1186/s13059-017-1224-0.

34.

Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.

Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S.

Oncotarget. 2017 Apr 18;8(16):27380-27392. doi: 10.18632/oncotarget.16068.

35.

Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.

Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL.

Oncotarget. 2017 Mar 21;8(12):20145-20164. doi: 10.18632/oncotarget.15525.

36.

Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2017 Jun;16(6):1114-1123. doi: 10.1158/1535-7163.MCT-16-0541. Epub 2017 Mar 6.

37.

Exosomes: From Garbage Bins to Promising Therapeutic Targets.

H Rashed M, Bayraktar E, K Helal G, Abd-Ellah MF, Amero P, Chavez-Reyes A, Rodriguez-Aguayo C.

Int J Mol Sci. 2017 Mar 2;18(3). pii: E538. doi: 10.3390/ijms18030538. Review.

38.

HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.

Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M.

Mol Cancer Ther. 2017 May;16(5):966-976. doi: 10.1158/1535-7163.MCT-16-0519. Epub 2017 Feb 21.

39.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

40.

Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.

Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK.

Cell Rep. 2016 Nov 1;17(6):1621-1631. doi: 10.1016/j.celrep.2016.10.020.

41.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2016 Oct 20;1(17):e87754. doi: 10.1172/jci.insight.87754.

42.

Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.

Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

Cancer Res. 2016 Dec 15;76(24):7194-7207. Epub 2016 Oct 14. Erratum in: Cancer Res. 2018 Jun 15;78(12):3402.

43.

Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p.

Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT.

Oncogene. 2017 Mar;36(10):1339-1350. doi: 10.1038/onc.2016.308. Epub 2016 Sep 26.

44.

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.

Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC Jr, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA.

Cancer Cell. 2016 Aug 8;30(2):273-289. doi: 10.1016/j.ccell.2016.06.020. Epub 2016 Jul 28.

45.

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.

Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER.

Cancer Cell. 2016 Jun 13;29(6):874-888. doi: 10.1016/j.ccell.2016.04.016.

46.

Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.

Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB.

Cell Rep. 2016 May 17;15(7):1493-1504. doi: 10.1016/j.celrep.2016.04.034. Epub 2016 May 5.

47.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

48.

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.

Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.

Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.

49.

Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.

Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R.

Oncotarget. 2016 Mar 22;7(12):15093-104. doi: 10.18632/oncotarget.7618.

50.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.

Mol Cell. 2016 Feb 18;61(4):640. doi: 10.1016/j.molcel.2016.02.006. Epub 2016 Feb 18. No abstract available.

Supplemental Content

Loading ...
Support Center